Certain Class B Common Stock of BioAtla, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2021.
June 13, 2021
Share
Certain Class B Common Stock of BioAtla, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2021. These Class B Common Stock will be under lockup for 181 days starting from 15-DEC-2020 to 14-JUN-2021.
Details:
The directors and executive officers, and substantially all of its shareholders have agreed they will not, subject to certain exceptions offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of capital stock or any securities convertible into, or exercisable or exchangeable for such capital stock, or publicly announce an intention to effect any such transaction, whether any transaction is to be settled by delivery of its common stock or such other securities, in cash or otherwise during the period ending 180 days after the date of this prospectus, without the prior written consent of J.P. Morgan Securities LLC, Jefferies LLC and Credit Suisse Securities (USA) LLC.
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
BIOATLA, INC. 
